SCHEMBL46302

SCHEMBL46302

Cc1ccc(-n2nc(C)cc2C)nc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2T Q9NPD8 1/20 0.60
MAPK10 P53779 2/20 0.51
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 5/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 4/20 0.48
PKM P14618 1/20 0.47
MAPT P10636 2/20 0.47
NPC1 O15118 1/20 0.47
RECQL P46063 1/20 0.47
RAB9A P51151 1/20 0.47
HTT P42858 1/20 0.46
TSHR P16473 3/20 0.46
HSD17B10 Q99714 3/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19121463 0.82 UBE2T (0.57) UBE2TMAPK10LMNASMN1; SMN2CASP3
SCHEMBL13757324 0.82 UBE2T (0.47) UBE2TMAPK10LMNASMN1; SMN2CASP3
SCHEMBL17166225 0.81 UBE2T (0.42) UBE2TMAPK10LMNASMN1; SMN2CASP3
SCHEMBL23222239 0.80 UBE2T (0.55) UBE2TMAPK10LMNASMN1; SMN2CASP3
SCHEMBL18997084 0.80 UBE2T (0.55) UBE2TMAPK10LMNASMN1; SMN2CASP3
SCHEMBL28240593 0.80 UBE2T (0.55) UBE2TMAPK10LMNASMN1; SMN2KDM4E
SCHEMBL18789253 0.78 KDM4E (0.59) UBE2TMAPK10LMNAKDM4EALDH1A1
SCHEMBL30630823 0.78 UBE2T (0.54) UBE2TMAPK10LMNASMN1; SMN2CASP3
SCHEMBL30401301 0.78 UBE2T (0.57) UBE2TMAPK10LMNASMN1; SMN2CASP3
SCHEMBL24409275 0.78 UBE2T (0.54) UBE2TMAPK10LMNASMN1; SMN2CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 WO disclosed
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed
WO-2011151436-A2 NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM EUROSCREEN S.A. (BE) 2011-12-08 WO disclosed
US-7579348-B2 Derivatives of 8-substituted xanthines PGXHEALTH, LLC (US) 2009-08-25 US disclosed
US-7579348-B2 Derivatives of 8-substituted xanthines PGXHEALTH, LLC (US) 2009-08-25 US disclosed
US-20070249598-A1 Derivatives of 8-substituted xanthines ADENOSINE THERAPEUTICS, LLC 2007-10-25 US disclosed
US-20070249598-A1 Derivatives of 8-substituted xanthines ADENOSINE THERAPEUTICS, LLC 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249598-A1 Derivatives of 8-substituted xanthines ADORA2B, ADORA2A, ADORA3 UBE2T 4130/4885MAPK10 3824/4885LMNA 2265/4885
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 UBE2T 3141/4885MAPK10 8/4885LMNA 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.